WHY IT MATTERS: If you currently rely on hemp-derived THC products for symptom management, this proposed one-year delay could preserve your access to those products in the near term, but the uncertainty means you should discuss backup treatment plans with your clinician now. CLINICAL OVERVIEW: Congressional action to delay a federal ban on hemp-derived THC products reflects the ongoing tension between rapidly expanding consumer access and the lack of regulatory frameworks to ensure product safety, accurate labeling, and appropriate dosing. From a clinical standpoint, a one-year delay could preserve current patient access to hemp-derived cannabinoid products while ideally providing time for meaningful safety standards to be developed.